Table 3.
Clinical efficacy of biological inhibitors of cytokines
| Cytokine Inhibition | Biologic | Effectiveness Proven | Ineffective |
|---|---|---|---|
| IL-1 | Anakinra | Juvenile arthritis and cryopyrin-associated periodic syndromes | RA |
| Canakinumab | |||
| Rilonacept | |||
| IL-6 | Tocilizumab | RA and juvenile arthritis | — |
| TNF-α | Adalimumab | RA, juvenile arthritis, ankylosing spondylitis, IBD, and psoriasis | Multiple sclerosis and ANCA vasculitis |
| Certolizumab | |||
| Etanercept | |||
| Golimumab | |||
| Infliximab | |||
| IL-12/IL-23 | Ustekinumab | Ankylosing spondylitis, IBD, and psoriasis | — |
| Briakinumab | |||
| IL-17 | Secukinumab | Ankylosing spondylitis and psoriasis | RA and IBD |
RA, rheumatoid arthritis; IBD, inflammatory bowel disease.